Search
for
Sort by
Research 541–570 of 1000+
- Biological Function of Long Non-coding RNA (LncRNA) Xist
- Mirtazapine-induced Gynecomastia: An Unknown Side Effect?
- Matriptase: Potent Proteolysis on the Cell Surface
- Protein Kinase C as a Therapeutic Target
- Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
- Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
- Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
- A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4
- Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
- Case Report: A Virilizing Adrenal Oncocytoma
- Saw Palmetto Extract Inhibits Metastasis and Antiangiogenesis through STAT3 Signal Pathway in Glioma Cell
- Amphiregulin in Fibrotic Diseases and Cancer
- Non-histone Methylation of SET7/9 and its Biological Functions
- Clinicopathological study of cutaneous adnexal cyst with some unusual presentation
- Hirsutism in a Female Adolescent Induced by Long-Acting Injectable Risperidone
- Mycosis Fungoides in Elderly Adults—A Diagnostic Challenge
- Robotic surgical systems in plastic and reconstructive surgery
- Matrigel uses in cell biology and for the identification of thymosin β4, a mediator of tissue regeneration
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Lung Cancer Awareness Symposium Highlights Necessary Focus Areas for Research
- Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
- Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
- Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors
- Tregs: Where We Are and What Comes Next?
- Top applications of dermatologic ultrasonography that can modify management
- Oncogenic senescence: a multi-functional perspective
- A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment <i>in vitro</i> and <i>in vivo</i>
- Radioprotection of Lung Tissue by Soy Isoflavones
- Formulation and optimization of folate-bovine serum albumin-coated ethoniosomes of pterostilbene as a targeted drug delivery system for lung cancer: In vitro and in vivo demonstrations